{
    "nct_id": "NCT06223659",
    "official_title": "Investigating the Use of EMLA Topical Cream for Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Cutaneous Cancers",
    "inclusion_criteria": "* Biologic males or females\n* 18 - 99 years of age\n* Histologically confirmed cutaneous melanoma, Merkel cell carcinoma, squamous cell carcinoma, or other cutaneous malignancy for which lymphoscintigraphy and sentinel lymph node biopsy has been recommended.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 99 Years",
    "exclusion_criteria": "* Known allergy or intolerance to EMLA cream, lidocaine, prilocaine, or any other local anesthetic\n* History of adhesive allergy\n* Contraindication to Tc99 injection for sentinel lymph node mapping\n* Incarcerated patients\n* Patients incapable of independently providing consent\n* Mucosal or genital lymphoscintigraphy site\n* Pregnancy\n* Participant self-declared or Ohio State University (OSU) medical chart listing chronic pain as a pre-existing diagnosis\n* Participants with chronic pain as defined by the Centers for Disease Control and Prevention (CDC):\"pain lasting 3 months or more that can be caused by a disease or condition, injury, medical treatment, or unknown reason\" excluding those with stable co-morbid conditions such as peripheral neuropathy, fibromyalgia, arthritis, and cancer-related pain who do not require narcotics. Patients who require narcotics at any time within the 7-day period leading up to the procedure",
    "miscellaneous_criteria": ""
}